PE anti-human CD31 Antibody

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 ?l per million cells in 100 ?l staining volume or 5 ?l per 100 ?l of whole blood.

Clone WM59 has been reported to recognize the D2 extracellular portion of CD31.

Additional reported applications (for the relevant formats) include: immunofluorescence microscopy², immunohistochemical staining of acetone-fixed frozen tissue sections⁸,　blocking of platelet aggregation³, and spatial biology (IBEX)^11,12. Clone WM59 is not recommended for immunohistochemical staining of formalin-fixed paraffin-embedded sections. The Ultra-LEAF? purified antibody (Endotoxin < 0.01 EU/?g, Azide-Free, 0.2 ?m filtered) is recommended for functional assays (Cat. No. 303143 & 303144).

The purified WM59 antibody is useful as a capture antibody for a sandwich ELISA assay, when used in conjunction with biotin anti-human CD31 antibody (Cat. No. 536604) antibody as the detection antibody.

Iterative Bleaching Extended multi-pleXity (IBEX) is a fluorescent imaging technique capable of highly-multiplexed spatial analysis. The method relies on cyclical bleaching of panels of fluorescent antibodies in order to image and analyze many markers over multiple cycles of staining, imaging, and, bleaching. It is a community-developed open-access method developed by the Center for Advanced Tissue Imaging (CAT-I) in the National Institute of Allergy and Infectious Diseases (NIAID, NIH).

1. Schlossman S, et al. Eds. 1995. Leucocyte Typing V Oxford University Press. New York.
2. Muczynski KA, et al. 2003. J. Am. Soc. Nephrol. 14:1336. (IF)
3. Wu XW, et al. 1997. Arterioscl. Throm. Vas. 17:3154. (Block)
4. Nagano M, et al. 2007. Blood 110:151. (FC) PubMed
5. MacFadyen JR, et al. 2005. FEBS Lett. 579:2569. PubMed
6. Yoshino N, et al. 2000. Exp. Anim. (Tokyo) 49:97. (FC)
7. Sestak K, et al. 2007. Vet. Immunol. Immunopathol. 119:21.
8. Wicki A, et al. 2012. Clin. Cancer Res. 18:454. (FC, IHC) PubMed
9. Oeztuerk-Winder F, et al. 2012. EMBO J. 31:3431. (FC) PubMed
10. Bushway ME, et al. 2014. Biol Reprod. 90(5): 110 (IF) PubMed
11. Radtke AJ,　et al. 2020.　Proc Natl Acad Sci USA. 117:33455-33465. (SB)　PubMed
12. Radtke AJ,　et al. 2022.　Nat Protoc. 17:378-401. (SB)　PubMed

1. Xin Y, et al. 2021. Stem Cell Res Ther. 49:12. PubMed
2. Liu C, et al. 2022. Regen Ther. 21:192. PubMed
3. Gao Q, et al. 2019. J Exp Med. 216:688. PubMed
4. Gong Y, et al. 2021. Aging (Albany NY). 13:20629. PubMed
5. Lu D, et al. 2022. Dis Markers. 2022:3556372. PubMed
6. Zhang J, et al. 2022. Int J Mol Sci. 23:. PubMed
7. Pettinato G, et al. 2019. Sci Rep. 9:8920. PubMed
8. Yu C, et al. 2020. Sci Rep. 10:14521. PubMed
9. Witkowski MT, et al. 2020. Cancer Cell. 37:867. PubMed
10. Alhaj Hussen K, et al. 2017. Immunity. 47:680. PubMed
11. Revel-Vilk S, et al. 2015. Clin Immunol. 159: 84-92. PubMed
12. Nagano M, et al. 2007. Blood . 110:151. PubMed
13. Nagai N, et al. 2018. PLoS Genet. 14:e1007826. PubMed
14. Zhang Y, et al. 2018. Stem Cells Int. 2018:7159465. PubMed
15. Xu P, et al. 2020. Cancer Immunol Res. 8:1193. PubMed
16. Dedeoglu B, et al. 2016. PLoS One. 11: 0150826. PubMed
17. Scherpenisse M, et al. 2021. MBio. 12:. PubMed
18. Iio K, et al. 2019. Sci Rep. 9:813. PubMed
19. Sun K, et al. 2022. Nat Commun. 13:4943. PubMed
20. Pan C, et al. 2019. Int J Mol Med. 44:1629. PubMed
21. Kerdidani D, et al. 2022. J Exp Med. 219:. PubMed
22. Dong N, et al. 2022. World J Stem Cells. 14:556. PubMed
23. Wei X, et al. 2019. Int J Mol Med. 44:1425. PubMed
24. Künzel K, et al. 2022. Heliyon. 8:e10365. PubMed
25. Khanh VC, et al. 2021. Stem Cells Dev. 30:758. PubMed

Monocytes, platelets, granulocytes, endothelial cells, lymphocyte subset

1. DeLisser H, et al. 1994. Immunol. Today 15:490.
2. Newman P, 1997. J. Clin. Invest. 99:3.
3. Fawcett J, et al. 1995. J. Cell Biol. 128:1229.